CA2959329C - Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia - Google Patents
Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia Download PDFInfo
- Publication number
- CA2959329C CA2959329C CA2959329A CA2959329A CA2959329C CA 2959329 C CA2959329 C CA 2959329C CA 2959329 A CA2959329 A CA 2959329A CA 2959329 A CA2959329 A CA 2959329A CA 2959329 C CA2959329 C CA 2959329C
- Authority
- CA
- Canada
- Prior art keywords
- temperature
- mixture
- aripiprazole
- surface area
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 143
- 230000008569 process Effects 0.000 title claims abstract description 117
- 239000000203 mixture Substances 0.000 title claims description 157
- 238000002425 crystallisation Methods 0.000 title description 82
- 230000008025 crystallization Effects 0.000 title description 82
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical class ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title description 39
- 238000013265 extended release Methods 0.000 title description 11
- 238000009472 formulation Methods 0.000 title description 10
- 201000000980 schizophrenia Diseases 0.000 title description 9
- 239000002245 particle Substances 0.000 claims abstract description 141
- 150000001875 compounds Chemical class 0.000 claims abstract description 56
- 239000013078 crystal Substances 0.000 claims abstract description 55
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 88
- 239000002904 solvent Substances 0.000 claims description 72
- 238000001816 cooling Methods 0.000 claims description 64
- 229940079593 drug Drugs 0.000 claims description 61
- 239000003814 drug Substances 0.000 claims description 61
- 238000000265 homogenisation Methods 0.000 claims description 40
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 34
- 229940011051 isopropyl acetate Drugs 0.000 claims description 34
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical group CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 238000013019 agitation Methods 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- DDINXHAORAAYAD-UHFFFAOYSA-N aripiprazole lauroxil Chemical compound C1=C2N(COC(=O)CCCCCCCCCCC)C(=O)CCC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl DDINXHAORAAYAD-UHFFFAOYSA-N 0.000 abstract description 103
- 229960003798 aripiprazole lauroxil Drugs 0.000 abstract description 103
- 238000002347 injection Methods 0.000 abstract description 27
- 239000007924 injection Substances 0.000 abstract description 27
- 125000001931 aliphatic group Chemical group 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 71
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 52
- 238000001953 recrystallisation Methods 0.000 description 41
- 229960004372 aripiprazole Drugs 0.000 description 33
- 230000000977 initiatory effect Effects 0.000 description 27
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 26
- 238000009826 distribution Methods 0.000 description 22
- 238000013400 design of experiment Methods 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 238000012546 transfer Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000003190 augmentative effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000010899 nucleation Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 230000006911 nucleation Effects 0.000 description 11
- 229940035044 sorbitan monolaurate Drugs 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 10
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 10
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 10
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 10
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 10
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- STDYTJDGBXCCRG-UHFFFAOYSA-N Aripiprazole cavoxil Chemical compound C1=C2N(COC(=O)CCCCC)C(=O)CCC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl STDYTJDGBXCCRG-UHFFFAOYSA-N 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 229940088679 drug related substance Drugs 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000007972 injectable composition Substances 0.000 description 6
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 6
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 6
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 238000010926 purge Methods 0.000 description 6
- 230000003134 recirculating effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 229940043232 butyl acetate Drugs 0.000 description 5
- 229940093499 ethyl acetate Drugs 0.000 description 5
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 5
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 5
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 229940090181 propyl acetate Drugs 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 5
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002131 composite material Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940056213 abilify Drugs 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000013529 heat transfer fluid Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- NUKZAGXMHTUAFE-UHFFFAOYSA-N methyl hexanoate Chemical compound CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WKVZMKDXJFCMMD-UVWUDEKDSA-L (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;azanide;n,3-bis(2-chloroethyl)-2-ox Chemical compound [NH2-].[NH2-].Cl[Pt+2]Cl.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 WKVZMKDXJFCMMD-UVWUDEKDSA-L 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- RDYWTOWUSVAZGN-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-1-(hydroxymethyl)-3,4-dihydroquinolin-2-one Chemical compound C1=C2N(CO)C(=O)CCC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl RDYWTOWUSVAZGN-UHFFFAOYSA-N 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- RCZNYTXJVULKCR-UHFFFAOYSA-N I.I.I.I.I.I.I.I Chemical compound I.I.I.I.I.I.I.I RCZNYTXJVULKCR-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011550 data transformation method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000010903 primary nucleation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010900 secondary nucleation Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041341P | 2014-08-25 | 2014-08-25 | |
| US62/041,341 | 2014-08-25 | ||
| PCT/US2015/046525 WO2016032950A1 (en) | 2014-08-25 | 2015-08-24 | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2959329A1 CA2959329A1 (en) | 2016-03-03 |
| CA2959329C true CA2959329C (en) | 2023-06-27 |
Family
ID=55347322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2959329A Active CA2959329C (en) | 2014-08-25 | 2015-08-24 | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10064859B2 (enExample) |
| EP (2) | EP3185867B1 (enExample) |
| JP (2) | JP6591546B2 (enExample) |
| CN (2) | CN107106556B (enExample) |
| AU (2) | AU2015306910B2 (enExample) |
| CA (1) | CA2959329C (enExample) |
| CY (1) | CY1124058T1 (enExample) |
| DK (1) | DK3185867T3 (enExample) |
| ES (2) | ES2994850T3 (enExample) |
| HR (1) | HRP20210551T1 (enExample) |
| HU (1) | HUE054641T2 (enExample) |
| IL (1) | IL250661B (enExample) |
| LT (1) | LT3185867T (enExample) |
| MA (2) | MA40480B1 (enExample) |
| PL (1) | PL3185867T3 (enExample) |
| PT (1) | PT3185867T (enExample) |
| RS (1) | RS61709B1 (enExample) |
| SI (1) | SI3185867T1 (enExample) |
| SM (1) | SMT202100212T1 (enExample) |
| WO (1) | WO2016032950A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ730571A (en) | 2012-09-19 | 2018-12-21 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| MA40480B1 (fr) * | 2014-08-25 | 2021-08-31 | Alkermes Pharma Ireland Ltd | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie |
| EP3294724A4 (en) * | 2015-05-08 | 2018-11-21 | Davuluri, Ramamohan Rao | Improved process for the preparation of aripiprazole with reduced particle size |
| WO2018104953A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate |
| US20200140410A1 (en) | 2017-07-28 | 2020-05-07 | Interquim, S.A. | Process for the preparation of aripiprazole lauroxil |
| CN110218209B (zh) * | 2018-03-02 | 2022-09-30 | 上海现代药物制剂工程研究中心有限公司 | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN113105389B (zh) * | 2021-04-16 | 2022-04-08 | 江苏海洋大学 | 一种阿立哌唑药物共晶及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| CA2543242C (en) * | 2003-10-23 | 2015-04-14 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof |
| HUE053904T2 (hu) | 2007-12-19 | 2021-07-28 | Janssen Pharmaceutica Nv | Hosszan tartó hatású injektálható paliperidon-észterekkel kapcsolatos adagolási rendek |
| US20110003823A1 (en) | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
| ES2639065T5 (es) | 2009-06-25 | 2023-01-30 | Alkermes Pharma Ireland Ltd | Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos |
| WO2012077134A1 (en) * | 2010-12-07 | 2012-06-14 | Ind-Swift Laboratories Limted | Process for preparing aripiprazole polymorphs |
| MX345460B (es) * | 2011-01-07 | 2017-02-01 | Neodyne Biosciences Inc | Dispositivos y metodos para tratamiento de heridas o de la piel. |
| PL2685979T3 (pl) | 2011-03-18 | 2017-02-28 | Alkermes Pharma Ireland Limited | Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20 |
| AU2013235519C1 (en) * | 2012-03-19 | 2018-04-26 | Alkermes Pharma Ireland Limited | Pharmaaceutical compositions comprising fatty acid esters |
| NZ730571A (en) * | 2012-09-19 | 2018-12-21 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
| MA40480B1 (fr) * | 2014-08-25 | 2021-08-31 | Alkermes Pharma Ireland Ltd | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie |
-
2015
- 2015-08-24 MA MA40480A patent/MA40480B1/fr unknown
- 2015-08-24 LT LTEP15836431.5T patent/LT3185867T/lt unknown
- 2015-08-24 JP JP2017530956A patent/JP6591546B2/ja active Active
- 2015-08-24 EP EP15836431.5A patent/EP3185867B1/en active Active
- 2015-08-24 PL PL15836431T patent/PL3185867T3/pl unknown
- 2015-08-24 ES ES21150116T patent/ES2994850T3/es active Active
- 2015-08-24 SM SM20210212T patent/SMT202100212T1/it unknown
- 2015-08-24 MA MA055917A patent/MA55917A/fr unknown
- 2015-08-24 AU AU2015306910A patent/AU2015306910B2/en active Active
- 2015-08-24 CN CN201580057857.XA patent/CN107106556B/zh active Active
- 2015-08-24 CA CA2959329A patent/CA2959329C/en active Active
- 2015-08-24 HU HUE15836431A patent/HUE054641T2/hu unknown
- 2015-08-24 PT PT158364315T patent/PT3185867T/pt unknown
- 2015-08-24 US US14/833,638 patent/US10064859B2/en active Active
- 2015-08-24 EP EP21150116.8A patent/EP3865476B1/en active Active
- 2015-08-24 WO PCT/US2015/046525 patent/WO2016032950A1/en not_active Ceased
- 2015-08-24 ES ES15836431T patent/ES2862098T3/es active Active
- 2015-08-24 HR HRP20210551TT patent/HRP20210551T1/hr unknown
- 2015-08-24 DK DK15836431.5T patent/DK3185867T3/da active
- 2015-08-24 CN CN202010375290.3A patent/CN111454207B/zh active Active
- 2015-08-24 SI SI201531576T patent/SI3185867T1/sl unknown
- 2015-08-24 RS RS20210433A patent/RS61709B1/sr unknown
-
2017
- 2017-02-19 IL IL250661A patent/IL250661B/en active IP Right Grant
-
2018
- 2018-07-24 US US16/043,721 patent/US10478434B2/en active Active
-
2019
- 2019-09-18 JP JP2019169473A patent/JP2019210296A/ja active Pending
- 2019-10-08 US US16/595,608 patent/US10973816B2/en active Active
-
2020
- 2020-11-04 AU AU2020264303A patent/AU2020264303B2/en active Active
-
2021
- 2021-03-24 US US17/211,352 patent/US11883394B2/en active Active
- 2021-04-13 CY CY20211100318T patent/CY1124058T1/el unknown
-
2023
- 2023-12-18 US US18/543,767 patent/US20240245676A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2959329C (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| CN100551365C (zh) | 制备紫杉醇亚微米颗粒的方法 | |
| CN1761454A (zh) | 小颗粒的制备方法 | |
| JP2017518341A (ja) | 非イオン界面活性剤を含む新規の薬学的組成物 | |
| JP4551988B2 (ja) | ２−メチル−チエノ−ベンゾジアゼピン製剤 | |
| US7417044B2 (en) | Tadalafil having a large particle size and a process for preparation thereof | |
| HK40057525B (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| HK40057525A (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| HK1246636A1 (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| HK1246636B (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| JP2897180B2 (ja) | 球晶状リボフラビンの製造方法 | |
| NZ729479B2 (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| KR102700719B1 (ko) | 덱사메타손 아세테이트를 포함하는 서방형 주사제제 및 그 제조방법 | |
| BR112019021366A2 (pt) | preparação de injeção de liberação sustentada que contém donepezil e método de preparação do mesmo | |
| Park et al. | Solid Dispersion of an HIV Protease Inhibitor | |
| HK1105193B (en) | Method of evaluating evenness of suplatast tosilate crystal, even crystal, and process for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |